Aminoguanidine and diabetic retinopathy

Diabetic retinopathy is a serious cause of blindness. Aminoguanidine inhibits the formation of protein non-enzymatic glycosylation end products, nitric oxide synthase activity, amine oxidase activity sensitive to hemicarbazide, and white blood cell stickiness in capillaries. Vascular endothelial growth factor, inhibition of aldose reductase, and prevention of oxidative modification of low-density lipoprotein can improve diabetic retinopathy.